Replies to post #109911 on Biotech Values

[DewDiligence]

Whatever, what's your response the rest of the post?

I think Susan Decker of Bloomberg must have misunderstood what she heard or thought she heard something that wasn’t said. If Bloomberg actually pulled the article, as you alleged, the reason was presumably that Decker recognized her mistake rather than some kind of censorship by MNTA (which strikes me as ridiculous).

Now to the main issue…

“They have built commercial inventory infringing our patents,” does not read like a hypothetical statement to me.

To reiterate, I doubt that Rick Shea actually said this.

So I would again submit that I do not think Teva would be using those processes if Lupenox was what they are manufacturing.

The source of Teva’s Lovenox knockoff and the tools Teva has used—or plans to use—to try to get FDA approval are related but separate issues, IMO. As far as I know, Teva’s Lovenox knockoff comes from the ItalFarmaco product that Lupin licensed to create the brand known as Lupenox, and ItalFarmaco’s product has not been altered by Teva. I do not have any information about the tools Teva has used to support its Lovenox ANDA or whether any of these tools could have been stolen from MNTA or copied from MNTA’s recently issued patents.

[oc631]

Huh! All morning, all I got was the first sentence and then the contact info. But you're right, it seems to be restored. Whatever, what's your response the rest of the post?

I experienced the same problem.